Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic

References

• Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Inf Dis. 2020;20(5):533–534.
   PubMed Web of Science ®Google Scholar
• WHO Coronavirus. (COVID-19) dashboard [cited 2022 Aug 7].https://covid19.who.int/?adgroupsurvey={adgroupsurvey}.
   Google Scholar
• Coronavirus (COVID-19) Vaccinations. ourworldindata.org. https://ourworldindata.org/covid-vaccinations. cited 2022 Aug 7.
   Google Scholar
• 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021. World Health Organisation. https://www.who.int/news/item/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021. cited 2022 Aug 29.
   Google Scholar
• COVID-19 Dashboard. Johns Hopkins University Coronavirus Resource Center. [cited 2022 Aug 29] https://coronavirus.jhu.edu/map.html
   Google Scholar
• VIEW-Hub. [cited 2022 Aug 29] https://view-hub.org/covid-19/effectiveness-studies
   Google Scholar
• Chuenkitmongkol S, Solante R, Burhan E, et al. Expert review on global real-world vaccine effectiveness against SARS-CoV-2 [published online ahead of print. Expert Rev Vaccines. 2022 Jun 30;1–14. 10.1080/14760584.2022.2092472.
   PubMed Web of Science ®Google Scholar
• Horne EMF, Hulme WJ, Keogh RH, et al. Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: openSAFELY cohort study using linked electronic health records. BMJ. 2022;378:e071249.
   PubMedGoogle Scholar
• Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv. 2021 cited 2021 Aug 21; Preprint. 10.1101/2021.08.06.21261707
   Google Scholar
• Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study. 2022 Jul 07.
   Google Scholar
• Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022;376:e069761.
   PubMedGoogle Scholar
• Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021;21(11):1507–1517.
   PubMed Web of Science ®Google Scholar
• Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;39911303–1312.
   PubMedGoogle Scholar
• Strasser Z, Hadavand A, Murphy S, et al. SARS-CoV-2 omicron variant is as deadly as previous waves after adjusting for vaccinations, demographics, and comorbidities. Res Square. 2022.
   Google Scholar
• Cuadros DF, Moreno CM, Musuka G, et al. Association between vaccination coverage disparity and the dynamics of the COVID-19 delta and omicron waves in the US. Front Med (Lausanne). 2022;9:898101. cited 2022 Jun 14.
   PubMed Web of Science ®Google Scholar
• Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis. 2022;22(7):1002–1010.
   PubMed Web of Science ®Google Scholar
• Spector T. What are the symptoms of omicron? 13 Jan 2022. [cited 2022 Aug 10] https://www1.racgp.org.au/newsgp/clinical/what-are-the-symptoms-of-omicron
   Google Scholar
• Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2. Retrospective Cohort Study BMJ. 2022;378:e070695
   PubMedGoogle Scholar
• Larrauri B, Malbrán A, Larrauri JA. Omicron and vaccines: an analysis on the decline in COVID-19 mortality. medRxiv. 2022. 10.1101/2022.05.20.222753966
   Google Scholar
• Liu Y, Yu Y, Zhao Y, et al. Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa. Int J Infect Dis. 2022;120:146–149.
   PubMed Web of Science ®Google Scholar
• Asia’s outbreaks show that Omicron is deadly in unvaccinated people. The Economist. [cited 2022 Aug 10] https://www.economist.com/graphic-detail/2022/04/09/asias-outbreaks-show-that-omicron-is-deadly-in-unvaccinated-people
   Google Scholar
• Kamp J, Onque R, Stancati M. Omicron deaths in U.S. exceed delta’s peak as covid-19 optimism rises in Europe [cited 22 Aug 10] https://www.wsj.com/articles/omicron-deaths-in-u-s-exceed-deltas-peak-as-covid-19-optimism-rises-in-europe-11643201653
   Google Scholar
• Fenit Nirappil F, Keating K. Covid deaths highest in a year as omicron targets the unvaccinated and elderly. [cited 22 Aug 10] https://www.washingtonpost.com/health/2022/02/08/omicron-deaths-covid/
   Google Scholar
• Shelton J. Omicron variant caused more excess deaths in massachusetts than delta. [cited 22 Aug 10] https://news.yale.edu/2022/05/20/omicron-variant-caused-more-excess-deaths-massachusetts-delta
   Google Scholar
• COVID-19 mortality in Australia, deaths registered to 2022 Jan 31. Australian Bureau of Statistics. https://www.abs.gov.au/articles/covid-19-mortality-australia-deaths-registered-31-january-2022#deaths-due-to-covid-19-in-australia.
   Google Scholar
• Weekly COVID-19 epidemiological update – region of the Americas. Issue 17, cited 2022 Jun 01. Pan American Health Organization. https://iris.paho.org/bitstream/handle/10665.2/56110/COVID-19Summary1June_eng.pdf?sequence=1&isAllowed=y.
   Google Scholar
• Mahase E. Omicron sub-lineage BA.2 may have “substantial growth advantage,” UKHSA reports. BMJ. 2022;376:o263.
   PubMedGoogle Scholar
• Callaway E. Why does the omicron sub-variant spread faster than the original? Nature. 2022;602(7898):556–557.
   PubMedGoogle Scholar
• UK Health Security Agency. COVID-19 vaccine surveillance report Week 4. 2022 Jan 27. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf.
   Google Scholar
• Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86–88.
   PubMed Web of Science ®Google Scholar
• Taylor L. Covid-19: hong kong reports world’s highest death rate as zero covid strategy fails. BMJ. 2022;376(o420):35177535.
   Google Scholar
• Control Centres for Disease Control. COVID-19 (SARS-CoV-2 infection) dashboard Taiwan2019 cited 2022 08 Aug 2022]. Available from 2022 08 Aug 2022 Aug 08: https://www.cdc.gov.tw/En.
   Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416.
   PubMed Web of Science ®Google Scholar
• Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27(12):2108–2110.
   PubMed Web of Science ®Google Scholar
• Cohn BA, Cirillo PM, Murphy CC, et al. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2022;375(6578):331–336.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Pritchard E, Matthews PC, et al. Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021;27(12):2127–2135.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83.
   PubMed Web of Science ®Google Scholar
• Mahumud RA, Ali MA, Kundu S, et al. Effectiveness of COVID-19 vaccines against delta variant (B.1.617.2): a meta-analysis. Vaccines (Basel). 2022;10(2):277.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Abu-Raddad LJ, Andrews N, et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the world health organization. Vaccine. 2022;40(26):3516–3527.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med. 2022;28(5):1063–1071.
   PubMed Web of Science ®Google Scholar
• Reeves J. US vaccination drive is bottoming out as omicron subsides. [cited 22 Aug 10] https://apnews.com/article/coronavirus-pandemic-health-us-news-alabama-4c0026679a346ea83a6a04f475a518ef
   Google Scholar
• Bariyo N, Parkinson J. As omicron surges, Africa’s covid-19 vaccination drive sputters. [cited 2022 Aug 10] https://www.wsj.com/articles/as-omicron-surges-africas-covid-19-vaccination-drive-sputters-11640358002
   Google Scholar
• Pradhan R, Recht H. As omicron surges, effort to vaccinate young children stalls. [cited 2022 Aug 10] https://www.nbcnews.com/health/health-news/omicron-surges-effort-vaccinate-young-children-stalls-rcna12173
   Google Scholar
• Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous coronavac or BNT162b2 vaccination. Nat Med. 2022;28(3):486–489.
   PubMed Web of Science ®Google Scholar
• Bonura F, Genovese D, Amodio E, et al. Neutralizing antibodies response against SARS-CoV-2 variants of concern elicited by prior infection or mRNA BNT162b2 Vaccination. Vaccines (Basel). 2022 May 30;10(6):874.
   PubMed Web of Science ®Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-CoV-2 delta and omicron variants following heterologous coronavac plus BNT162b2 booster vaccination. Nat Med. 2022;28(3):481–485.
   PubMed Web of Science ®Google Scholar
• van Gils MJ, Lavell A, van der Straten K, et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: a prospective cohort study. PLoS Med. 2022 May 17;19(5):e1003991.
   PubMed Web of Science ®Google Scholar
• Dolgin E. Omicron thwarts some of the world’s most-used COVID vaccines. Nature. 2022;601(7893):311.
   PubMed Web of Science ®Google Scholar
• Prillaman M. One coronavirus infection wards off another - but only if it’s a similar variant [published online ahead of print, 2022 Jul 14]. Nature. 2022. 10.1038/d41586-022-01914-6
   Google Scholar
• Patel DR, Field CJ, Septer KM, et al. Transmission and protection against reinfection in the ferret model with the SARS-CoV-2 USA-WA1/2020 reference isolate. J Virol. 2021;95(13):e0223220.
   PubMed Web of Science ®Google Scholar
• Dyer O. Covid-19: south Africa’s surge in cases deepens alarm over omicron variant. BMJ. 2021;375:n3013.
   PubMedGoogle Scholar
• Chen J, Wang R, Gilby NB, et al. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022;62(2):412–422.
   PubMed Web of Science ®Google Scholar
• Enhancing response to Omicron SARS-CoV-2. variant: technical brief and priority actions for member states World Health Organization HQ: headquarters, Geneva, Switzerland. World Health Organization [cited 2022 Aug 10]. https://www.who.int/docs/default-source/coronaviruse/2022-01-07-global-technical-brief-and-priority-action-on-omicron—corr2.pdf?sfvrsn=918b09d_20
   Google Scholar
• Potential rapid increase of omicron variant infections in the United States [cited 2022 Aug 10]. https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical-modeling-outbreak.html
   Google Scholar
• Covid News: U.S. Hospitalizations break record as omicron surges [cited 2022 Aug 10]. https://www.nytimes.com/live/2022/01/10/world/omicron-covid-testing-vaccines
   Google Scholar
• Kupferschmidt P, Vogel G. Omicron cases are exploding. Scientists still don’t know how bad the wave will be [cited 2022 Aug 10]. https://www.science.org/content/article/omicron-cases-are-exploding-scientists-still-don-t-know-how-bad-wave-will-be
   Google Scholar
• Butler M. No time for complacency in battle with COVID-19 [cited 2022 Aug 10]. https://www.health.gov.au/ministers/the-hon-mark-butler-mp/media/no-time-for-complacency-in-battle-with-covid-19
   Google Scholar
• The Editorial Board. Living with Covid-19 requires caution, not complacency [cited 2022 Aug 10]. https://www.ft.com/content/89451b07-9121-4a6d-b2f8-097c8cb02b67
   Google Scholar
• Lovett S. Covid vaccines: government warned of ‘dangerous complacency’ as millions skip boosters [cited 2022 Aug 10]. https://www.independent.co.uk/news/health/covid-booster-jab-vaccine-latest-uk-b2124200.html
   Google Scholar
• Wirawan GBS, Harjana NPA, Nugrahani NW, et al. Health beliefs and socioeconomic determinants of COVID-19 booster vaccine acceptance: an Indonesian cross-sectional study. Vaccines (Basel). 2022 May 5;10(5):724.
   PubMed Web of Science ®Google Scholar
• Navin MC, Oberleitner LM, Lucia VC, et al. COVID-19 vaccine hesitancy among healthcare personnel who generally accept vaccines. J Community Health. 2022;47(3):519–529.
   PubMed Web of Science ®Google Scholar
• Vanegas E, Robles-Velasco K, Osorio MF, et al. Adverse reactions following COVID−19 vaccination: an ecuadorian experience. Ann Med Surg (Lond). 2021 Dec; 72:103044. Epub 2021 NOV 18.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV−19) covid−19 vaccine. N Engl J Med. 2021 Dec 16;385(25):2348–2360. Epub 2021 Sep 29.
   PubMed Web of Science ®Google Scholar
• Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV−2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 Jul;21(7):939–949. Epub 2021 Apr 27.
   PubMed Web of Science ®Google Scholar
• Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID−19 vaccine type and adverse effects following vaccination. JAMA Network Open. 2021 Dec 1;4(12):e2140364.
   PubMed Web of Science ®Google Scholar
• Fragkou PC, Dimopoulou D. Serious complications of COVID-19 vaccines: a mini-review. Metabol Open. 2021 Dec;12:100145Epub 2021 Oct 30. PMID: 34746732; PMCID: PMC8556676.
   PubMedGoogle Scholar
• Oliver S. Considerations for booster doses of COVID-19 vaccines. MSPH ACIP Meeting 2021 Aug 13 https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-13/05-COVID-Oliver-508.pdf
   Google Scholar
• Interim statement on the use of additional booster doses of emergency use listed mRNA vaccines against COVID-19 2022 May 17 https://www.who.int/news/item/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19.
   Google Scholar
• How many vaccine booster doses have been administered? [cited 2022 Aug 10]. https://ourworldindata.org/covid-vaccinations#how-many-vaccine-doses-have-been-administered-in-total
   Google Scholar
• Holder J. Tracking coronavirus vaccinations around the world [cited 2022 Aug 10]. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html
   Google Scholar
• Urrunaga-Pastor D, Fernandez-Guzman D, Caira-Chuquineyra B, et al. Prevalence and factors associated with not receiving the booster dose of the COVID-19 vaccine in adults in Latin America and the Caribbean [published online ahead of print. Travel Med Infect Dis. 2022 Aug 9;50:102409.
   PubMed Web of Science ®Google Scholar
• Wee SL, Cave D, Dooley B. How asia, once a vaccination laggard, is revving up inoculations [cited 2022 Aug 10]. https://www.nytimes.com/2021/09/30/business/economy/asia-covid-vaccinations.html
   Google Scholar
• Gaffney A, Himmelstein DU, McCormick D, et al. Disparities in COVID-19 vaccine booster uptake in the USA: december 2021–February 2022. J Gen Intern Med. 2022;37(11):2918–2921.
   PubMed Web of Science ®Google Scholar
• European centre for disease prevention and control COVID-19 vaccine tracker [cited 2022 Aug 10]. https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
   Google Scholar
• European centre for disease prevention and control country overview report: week 31 2022. [cited 2022 Aug 10] https://covid19-country-overviews.ecdc.europa.eu/
   Google Scholar
• Global COVID-19 vaccination strategy in a changing world: july 2022 update. https://www.who.int/publications/m/item/global-covid-19-vaccination-strategy-in-a-changing-world–july-2022-update cited 22 Aug 10 .
   Google Scholar
• Cerqueira-Silva T, Shah SA, Robertson C , et al. Waning of mRNA boosters after homologous primary series with BNT162b2 or ChadOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: a test-negative design case-control study. cited 22 Aug 10. Available at SSRN: 10.2139/ssrn.4082927.
   Google Scholar
• Chariyalertsak S, Intawong K, Chalom K, et al. Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand. Res Square. 2022.
   Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr 21;38616:1532–1546. Epub 2022 Mar 2.
   PubMed Web of Science ®Google Scholar
• Fleming-Dutra KE, Britton A, Shang N, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance. JAMA. 2022 Jun 14;327(22):2210–2219.
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. COVID-19 vaccine surveillance report: week 6, 10 February 2022. cited 2022 Feb 13. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6.pdf
   Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA. 2022;327(7):639–651.
   PubMed Web of Science ®Google Scholar
• Florentino PTV, Millington T, Cerqueira-Silva T, et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study [published online ahead of print, 2022 Aug 8]. Lancet Infect Dis. 2022;22(11):1577–1586.
   PubMed Web of Science ®Google Scholar
• De-Leon H, Aran D. Over- and under-estimation of vaccine effectiveness. medRxiv. 2022. DOI:10.1101/2022.01.24.22269737
   Google Scholar
• Williams LR, Ferguson NM, Donnelly CA, et al. Measuring vaccine efficacy against infection and disease in clinical trials: sources and magnitude of bias in COVID-19 vaccine efficacy estimates [published online ahead of print, 2021 Oct 26]. Clin Infect Dis. 2021. DOI:10.1093/cid/ciab914
   Web of Science ®Google Scholar
• Tran TN, Wikle NB, Yang F, et al. SARS-CoV-2 attack rate and population immunity in Southern New England, march 2020 to may 2021. JAMA Network Open. 2022;5(5):e2214171.
   PubMed Web of Science ®Google Scholar
• Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 states, august 2021-january 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255–263.
   PubMed Web of Science ®Google Scholar
• Girard B, Tomassini JE, Deng W, et al. mRNA-1273 vaccine-elicited neutralization of SARS-CoV-2 omicron in adolescents and children. medRxiv [Preprint]. 2022 Jan; 25. 10.1101/2022.01.24.22269666.
   Google Scholar
• Patalon T, Saciuk Y, Peretz A, et al. Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. Nat Commun. 2022;13(1):3203.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl J Med. 2021;385(24):e85.
   PubMed Web of Science ®Google Scholar
• Veneti L, Berild JD, Watle SV, et al. Vaccine effectiveness with BNT162b2 (comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 delta and omicron infection among adolescents, Norway, August 2021 to January 2022. medRxiv. 2022. 10.1101/2022.03.24.22272854.
   Google Scholar
• Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob Health. 2022;10(6):e798–e806.
   PubMed Web of Science ®Google Scholar
• Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. Vaccines (Basel). 2022;10(1):86.
   PubMed Web of Science ®Google Scholar
• Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med. 2022;386(18):1712–1720.
   PubMed Web of Science ®Google Scholar
• Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA covid-19 vaccine in a nationwide setting. N Engl J Med. 2022;386(17):1603–1614.
   PubMed Web of Science ®Google Scholar
• Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med. 2022;28(7):1486–1490.
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377–1380.
   PubMed Web of Science ®Google Scholar
• Gazit S, Saciuk Y, Perez G, et al. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative. case-control study BMJ. 2022;377:e071113.
   PubMedGoogle Scholar
• Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of COVID-19 vaccine among long-term care residents in Ontario, Canada. medRxiv. 2022. 10.1101/2022.04.15.22273846.
   Google Scholar
• Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis BMC Med 2022 cited 2022 May 23; 20(1) 200
   PubMed Web of Science ®Google Scholar
• Di Fusco M, Lin J, Vaghela S, et al. COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. Expert Rev Vaccines. 2022 Apr;21(4):435–451. Epub 2022 Feb 3
   PubMed Web of Science ®Google Scholar
• Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COIVD-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults – nine states, january-september 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1553–1559.
   PubMed Web of Science ®Google Scholar
• Baum U, Poukka E, Leino T, et al. High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. MedRxiv. 2022.
   Google Scholar
• Adams K, Rhoads JP, Surie D, et al. Vaccine effectiveness of primary series and booster doses against omicron variant COVID-19-associated hospitalization in the United States. medRxiv. 2022.
   Google Scholar
• Mutambudzi M, Niedzwiedz C, Macdonald EB, et al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants. Occup Environ Med. 2021;78(5):307–314.
   Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2022;10(7):689–699.
   PubMed Web of Science ®Google Scholar
• Pearson CAB, Edmunds WJ, Hladish TJ, et al. Potential test-negative design study bias in outbreak settings: application to Ebola vaccination in Democratic Republic of Congo. Int J Epidemiol. 2022;51(1):265–278.
   PubMed Web of Science ®Google Scholar
• Dean NE, Hogan JW, Schnitzer ME. Covid-19 vaccine effectiveness and the test-negative design. N Engl J Med. 2021;385(15):1431–1433.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2021 Apr 14 COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB.https://www.ema.europa.eu/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-april-2021_en.pdf
   Google Scholar
• UK Medicines and Healthcare Products Regulatory Agency. Decision ARCHIVE: information for healthcare professionals on COVID-19 vaccine Pfizer/BioNTech (regulation 174). cited 2022 Aug 16. https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-healthcare-professionals-on-pfizerbiontech-covid-19-vaccine.
   Google Scholar
• UK Medicines and Healthcare Products Regulatory Agency. Decision. summary of product characteristics for spikevax. cited 2022 Jun 17 https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna.
   Google Scholar
• MHRA. Coronavirus vaccine - weekly summary of Yellow Card reporting. cited Apr 29. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting. cited 2021 May 20
   Google Scholar
• U.S. Centers for disease control and prevention. Myocarditis and Pericarditis. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html. cited 22 Aug 10
   Google Scholar
• UK Medicines and Healthcare Products Regulatory Agency. Decision. summary of product characteristics for vaxzevria. cited 2022 Jun 27. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca.
   Google Scholar
• Munro APS, Janani L, Cornelius V, Munro APS, Janani L, Cornelius V, et al. COV-BOOST study group. Safety and immunogenicity of seven COVID-19. vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021 Dec 18;398(10318):2258–2276.
   PubMed Web of Science ®Google Scholar
• Heterologous primary and booster COVID-19 vaccination. Evidence based regulatory considerations. https://www.ema.europa.eu/en/documents/report/heterologous-primary-booster-covid-19-vaccination-evidence-based-regulatory-considerations_en.pdf. cited 22 Aug 10
   Google Scholar
• Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022 Feb;28(2):410–422.Epub 2021 Dec 14
   PubMed Web of Science ®Google Scholar
• Whiteley WN, Ip S, Cooper JA, et al. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: a population-based cohort study of 46 million adults in England. PloS Med. 2022 Feb 22;19(2):e1003926.
   PubMed Web of Science ®Google Scholar
• Burn E, Li X, Delmestri A, et al. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis. medRxiv. 2021; Preprint. 10.1101/2021.07.29.21261348.
   PubMedGoogle Scholar
• Burn E, Roel E, Pistillo A, et al. Thromboembolic events and thrombosis with thrombocytopenia after COVID-19 infection and vaccination in Catalonia. Spain, 2021. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3886421
   Google Scholar
• Ab Rahman N, Lim MT, Lee FY, et al. Risk of serious adverse events after the BNT162b2, coronavac, and ChAdOx1 vaccines in Malaysia: a self-controlled case series study. Vaccine. 2022 Jul 30; 40(32):4394–4402.Epub 2022 Jun 3
   PubMed Web of Science ®Google Scholar
• Sanders B, Koldijk M, Schuitemaker H. Inactivated viral vaccines. vaccine analysis: strategies. Principles Control. 2014Nov;28:45–80.
   Google Scholar
• Sturkenboom M, Messina D, Paoletti O, et al. Cohort monitoring of 29 adverse events of special interest prior to and after COVID-19 vaccination in four large European electronic healthcare data sources. medRxiv. 2022.
   Google Scholar
• Yamey G, Garcia P, Hassan F, et al. It is not too late to achieve global covid-19 vaccine equity. BMJ. 2022;376:e070650.
   PubMedGoogle Scholar
• Vaezi A, Meysamie A. COVID-19 vaccines (basel) cost-effectiveness analysis: a scenario for Iran. Vaccines (Basel). 2022;10:37.
   Google Scholar
• Wang WC, Fann JC, Chang RE, et al. Economic evaluation for mass vaccination against COVID-19. J. J Formos Med Assoc. 2021;120 Suppl 1:S95–S105.
   PubMed Web of Science ®Google Scholar
• Reicher S, Drury J. Pandemic fatigue? How adherence to covid-19 regulations has been misrepresented and why it matters. BMJ. 2021;372:n137.
   PubMed Web of Science ®Google Scholar
• Bodas M, Kaim A, Velan B, et al. Overcoming the effect of pandemic fatigue on vaccine hesitancy-Will belief in science triumph? [published online ahead of print, 2022 Apr 7]. J Nurs Scholarsh. 2022. https://sigmapubs.onlinelibrary.wiley.com/doi/10.1111/jnu.12778
   PubMed Web of Science ®Google Scholar
• Sanders B, Koldijk M, Schuitemaker H. Inactivated Viral Vaccines. Vaccine Analysis. 2014Nov;28:45–80.
   Google Scholar
• Jaramillo-Monge J, Obimpeh M, Vega B, et al. COVID-19 vaccine acceptance in azuay province, ecuador: a cross-sectional online survey. Vaccines (Basel). 2021;9(6):678.
   PubMed Web of Science ®Google Scholar
• Matos CCSA, Gonçalves BA, Couto MT. Vaccine hesitancy in the global south: towards a critical perspective on global health. Glob Public Health. 2022Jun;17(6):1087–1098. Epub 2021 Apr 11. PMID: 33843459.
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–228. Medline:33082575.
   PubMed Web of Science ®Google Scholar
• Tagoe ET, Sheikh N, Morton A, et al. COVID-19 vaccination in lower-middle income countries: national stakeholder views on challenges, barriers, and potential solutions. Front Public Health. 2021;9:709127.
   PubMed Web of Science ®Google Scholar
• Fernandez-Guzman D, Chavez-Cruzado E, Diaz-Velez C, et al. Advances and challenges in COVID-19 vaccination in Latin American: a public health perspective. Infectio. 2022;26(4):441–449.
   Google Scholar
• Slaoui M, Hepburn M. Developing safe and effective covid vaccines — operation warp speed’s strategy and approach. N Engl J Med. 2020;383(18):1701–1703.
   PubMed Web of Science ®Google Scholar
• Rodríguez M. BBC News Mundo – los países en América Latina en los que desarrollan proyectos de vacunas contra la covid-19. 2021. https://www.bbc.com/mundo/noticias-america-latina-56545330 cited 22 Aug 10.
   Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020 Dec 10;383(24):2320–2332. Epub 2020 Sep 2. PMID: 32877576; PMCID: PMC7494251.
   PubMed Web of Science ®Google Scholar
• Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. 2021, reuters. Available at https://www.reuters.com/article/brief-novavax-covid-19-vaccine-demonstra-idUSB8N2ES01Q [cited 2022 Oct 24].
   Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al., Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• Peshimam GN, Farooq U. CanSinoBIO’s COVID-19 vaccine 65.7% effective in global trials, Pakistan official says. 2021, Reuters. Available at https://www.reuters.com/article/us-health-coronavirus-vaccine-pakistan-idUSKBN2A81N0 cited 2021 Feb 26.
   Google Scholar